Noven Pharmaceuticals, Inc. has agreed to acquire JDS Pharmaceuticals, LLC for approximately $125 million in cash and take on approximately $10 million in liabilities. JDS is a privately-held specialty pharmaceutical company that currently markets two branded prescription psychiatry products and has in its pipeline potential products in psychiatry and women’s health. The acquisition provides Noven with two marketed products, a next-gen psychiatric pipeline that includes one pending ND...